J&J’s Janssen Partners with BioSymetrics for Predicting Onset and Severity of COVID-19 Using Machine Learning

(Beerse, Belgium) has entered into a collaboration with BioSymetrics Inc. (New York, NY, USA) and Sema4 (Stamford, CT, USA) that will focus on predicting the onset and severity of COVID-19 among different populations using machine learning.

As part of the collaboration, the parties will use BioSymetrics' Contingent-AI engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease. BioSymetrics, a biomedical artificial intelligence company that provides clinical insights and helps researchers develop drugs with greater speed and precision, has developed the platform based on a patent pending AI iteration framework that can be used in conjunction with clinical research to predict target mechanism, identify lead compounds, or provide clinical insights. The collaboration will operate across several projects with a goal of enabling a vaccine and course of treatment against SARS-CoV-2.

"We've been working on deploying AI in the clinical setting for several years," said Anthony Iacovone, Co-Founder and Chairman of BioSymetrics. "We've demonstrated that machine learning can bring speed and precision to helping identify at risk patient populations, predict disease outcomes, and build better treatments, but the pandemic has now pushed biomedical AI technology to the fore front of innovative necessity."

"There is dramatic heterogeneity within the COVID-19 patient groups and a spectrum of disease risk that must be interpreted probabilistically – something of which I believe this collaboration will drive through innovation and combined expertise," added Eric Schadt, Founder and CEO of Sema4, a patient-centered health intelligence company.

Related Links:

BioSymetrics Inc.
Sema4
Johnson & Johnson
Janssen Pharmaceuticals Inc.